Health Care · Electromedical & Electrotherapeutic Apparatus

TMDX TransMedics Group, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 175626275 filings
Russell 2000

TMDX at a glance

TransMedics Group, Inc. (TMDX, SEC CIK 1756262) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), TransMedics Group, Inc. (TMDX) reported revenue of $605.5 million (up 37.1% from FY2024) and net income of $190.3 million. Diluted EPS was $4.87.
  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding TransMedics Group, Inc. (TMDX) shares worth $1.3 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by TOBIN JAMES R on November 9, 2026 of 59 shares at $93.96 per share.
  • In the last 90 days, TMDX insiders reported 1 open-market purchase ($109K) and 2 open-market sales ($385K) on Form 4, a net sale of $276K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$605.5M
+37.1% vs prior year
Insiders · 90 days
1 buy · 2 sells
Net −$276K
13F holders
27 funds
$1.3B · −4 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Medical technology company providing OCS platform and NOP services to improve organ transplant therapy for heart, lung, and liver
  • New emphasis on NOP expansion with acquisition of Summit Aviation and 22 fixed-wing aircraft to enhance national organ transportation logistics
  • Strategic pivot toward integrating comprehensive transplant logistics, including owning aircraft, to become a full-service U.S. organ procurement provider
  • Revenue growth to $605.5M in 2025, up 37.1% YoY; total employees 898 worldwide, mostly U.S.-based
  • Commenced transition to new corporate headquarters in Somerville, MA, to support expansion and operations consolidation by 2028

Risk Factors

  • Leverage risk from $460M Notes issued May 2023, 1.50% interest, maturing June 2028
  • Macroeconomic exposure to long-term Somerville lease, $23.9M annual base rent starting 2028, escalating 2-3% annually
  • Supply chain risk from $4.0M noncancellable manufacturing purchase commitment through 2029
  • Competitive risk from reliance on sales of organ-specific disposable OCS Perfusion Sets and Consoles amid evolving organ transplant tech
  • Operational risk in international expansion with $42.9M spent on fixed-wing aircraft for transplant logistics in 2025

Management Discussion & Analysis

  • Convertible Senior Notes issued $460M, net proceeds $393.3M after $52.1M capped call costs and $14.6M issuance costs, interest 1.50%
  • CIBC credit facility borrowings $60M, interest rate min 3.5% to 4.0% plus spreads, repayment starting July 2026, maturity July 2027
  • Cash expected to fund operations, capex, debt service for 12+ months; potential future capital raises may be needed
  • Risks include capacity expansion, regulatory approvals, reimbursement, competition, operating cost increases, and new product development

AI summary of the TMDX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $203.0M, up $59.2M YoY from $143.8M
  • Gross margin 58% vs 59% YoY, product margin 79% vs 79%
  • OCS Liver strongest, $150.2M vs $107.9M; OCS Lung weakest, $3.1M vs $3.7M
  • Cash $493.0M; nine-month operating cash flow $77.8M vs $158.3M
  • Outlook: revenue growth from NOP and international expansion, with tariff, supply-chain and reimbursement risks

Risk Factors

  • No material changes to risk factors since the 2025 Form 10-K
  • Carried-forward business risks remain detailed in the 2025 Form 10-K
  • No new regulatory, legal, operational, market, or financial risks identified

AI summary of the TMDX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for the quarter ended September 30, 2026
  • Full operating and financial details available in Exhibit 99.1, the company’s earnings press release

Item EX-99.1: Item EX-99.1

  • Q3 revenue $203.0M, up 41%, with organic growth 35%, confirming strong OCS adoption and logistics demand
  • Service revenue $89.6M, up 60%, outpaced product revenue growth and increased mix pressure on gross margin
Filed Sep 10, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Leadership transition announced September 10, 2026, signaling a management change relevant to strategic execution
  • Exhibit 99.1 contains the specific executive changes, effective dates, and succession details investors should review

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Fernando Araujo appointed CFO and Treasurer effective September 21, 2026, succeeding Gerardo Hernandez
  • Araujo brings 2023–2026 CFO experience at GE HealthCare’s Advanced Imaging Solutions

Item EX-99.1: Item EX-99.1

  • Fernando Araujo becomes CFO September 21, 2026, bringing more than 20 years of GE HealthCare, GE, and 3M finance leadership
  • Gerardo Hernandez shifts to Commercial Strategic Advisor, LATAM, aligning finance succession with planned Latin America expansion
Filed Aug 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results covered quarter ended June 30, 2026
  • Results announced August 4, 2026 through Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Q2 revenue $189.9M, up 21%, led by service revenue growth of 29% to $78.8M
  • GAAP operating margin fell to 12.5% from 23.2% as operating expenses rose 49% to $89.5M

AI summaries of TMDX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for TMDX

Don't miss the next TMDX filing

  • Alerts as it files. A push when TMDX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut TMDX, by share count.
  • Ask anything. An AI agent that reads every TMDX filing and answers with sources.

TMDX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
TOBIN JAMES RSellNov 9, 2026$93.96
TOBIN JAMES RSellNov 9, 2026$94.98
Araujo Fernando N.AOct 28, 2026-
Araujo Fernando N.AOct 28, 2026-
Weill DavidBuySep 11, 2026$81.63
TOBIN JAMES RGAug 17, 2026-
Hassanein Waleed HAJul 10, 2026-
Hernandez GerardoAJul 10, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$241.6M$441.5M$605.5M
Gross Profit-$262.1M$362.8M
Operating Income-$37.5M$108.6M
Net Income-$35.5M$190.3M
Gross Margin-59.4%59.9%
Op. Margin-8.5%17.9%
Net Margin-8.0%31.4%
Balance Sheet
Total Assets-$804.1M$1.1B
Equity$137.2M$228.6M$473.1M
ROE-15.5%40.2%
Per Share
EPS-$1.01$4.87
Cash Flow
Operating CF-$48.8M$192.8M
CapEx-$129.7M$59.3M

Source: XBRL data in TransMedics Group, Inc. (TMDX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate TMDX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
TMDX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$1.27B
Q2 202631$1.37B
Q1 202631$2.15B
Q4 202532$2.65B
Q3 202533$2.47B
Q2 202529$2.78B
Q1 202525$1.01B
Q4 202426$764.8M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.

Source: 13F-HR filings on SEC EDGAR (aggregated from 234 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

TMDX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 12, 2026--
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
4Oct 30, 2026--
4Sep 14, 2026--
8-KSep 10, 2026Analysis-
4Aug 17, 2026--
10-QAug 4, 2026Analysis
8-KAug 4, 2026Analysis-
4Jul 14, 2026--
4Jul 14, 2026--
4Jul 14, 2026--
4Jun 17, 2026--
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
4May 22, 2026-
8-KMay 21, 2026Analysis
4May 21, 2026-
8-KMay 5, 2026Analysis-
10-QMay 5, 2026Analysis
SC 13GApr 30, 2026-

Related Health Care companies

All Health Care →

TMDX SEC filings: frequently asked questions

Are TMDX insiders buying or selling?

In the last 90 days, TransMedics Group, Inc. (TMDX) officers, directors and 10% owners reported 1 open-market purchase worth $109,058 by 1 insider and 2 open-market sales worth $385,464 by 1 insider on Form 4, a net sale of $276,406. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold TMDX stock?

As of September 30, 2026, the largest TransMedics Group, Inc. (TMDX) holders among the 13F filers tracked by SignalX were BlackRock ($458.2 million), Vanguard Portfolio Management LLC ($152.3 million), Vanguard Capital Management LLC ($125.0 million), State Street Corp ($119.0 million), Goldman Sachs Group ($76.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was TMDX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), TransMedics Group, Inc. (TMDX) reported revenue of $605.5 million (up 37.1% from FY2024) and net income of $190.3 million. Diluted EPS was $4.87. The figures come from the XBRL data in the 10-K.

What are the main risks in TMDX's latest 10-K?

In the 10-K filed February 24, 2026, TransMedics Group, Inc. (TMDX) flagged: Leverage risk from $460M Notes issued May 2023, 1.50% interest, maturing June 2028. Macroeconomic exposure to long-term Somerville lease, $23.9M annual base rent starting 2028, escalating 2-3% annually. (AI summary of the Risk Factors section.)

What did TMDX report in its latest 8-K?

TransMedics Group, Inc. (TMDX) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for the quarter ended September 30, 2026.

What are the latest TMDX SEC filings?

TransMedics Group, Inc. (TMDX) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 12, 2026.

What is TMDX's SEC CIK number?

TransMedics Group, Inc. (TMDX)'s SEC Central Index Key (CIK) is 1756262. EDGAR lists every TMDX filing under that number.

Ask anything about TMDX

The research agent reads TMDX's filings, financials, insider trades and 13F holders, then answers with sources.